
Over-Spec as Omotenash_ Why Japanese Quality Culture Rejects the Crooked Cucumber
Over-Spec as Omotenashi
Why Japanese Quality Culture Rejects the Crooked Cucumber
Japan has long been associated with quality.
Japanese manufacturers are known for precision, consistency, attention to detail, and an almost obsessive determination to prevent defects.
But there is another side to this reputation.
Sometimes, Japan does not simply meet the required standard.
It exceeds it.
And sometimes, it exceeds it by a considerable margin.
In manufacturing and quality assurance, we might call this “over-specification” — or simply, over-spec.
Yet in Japan, over-spec is not always regarded as wasteful or irrational.
It can be seen as a form of omotenashi.
The Crooked Cucumber
Consider a simple cucumber.
It is fresh.
It is safe.
It tastes exactly as it should.
But it is crooked.
In many Japanese supermarkets, consumers have traditionally expected vegetables to have a remarkably uniform appearance. Cucumbers should be straight. Apples should look beautiful. Packages should be pristine.
A crooked cucumber may therefore be treated as lower grade, even though its essential function as food has not changed.
This raises a deceptively simple question:
Is straightness really a quality attribute?
From the perspective of safety and nutrition, probably not.
From the perspective of customer expectations, however, the answer may historically have been different.
This small cucumber illustrates something much larger about Japanese quality culture.
We often do not stop at:
“Does it meet the specification?”
Instead, we ask:
“Can we make it even better?”
Quality Beyond the Global Standard
The same mentality can appear in pharmaceutical and biotechnology development.
A regulation establishes a requirement.
An international guideline describes an acceptable framework.
Scientific evidence indicates an appropriate control strategy.
Yet an organization may decide:
“We should set a stricter internal standard.”
The intention is usually good.
A tighter specification appears safer.
More testing appears more reliable.
More documentation appears more compliant.
Additional controls appear to reduce risk.
And another review step appears to prevent mistakes.
One by one, these decisions seem reasonable.
Eventually, however, the organization may find itself operating far beyond what is scientifically necessary or internationally expected.
The result is over-spec.
Over-Spec Is Not Necessarily Bad
We should be careful not to dismiss this culture.
Japan’s extraordinary attention to quality helped create global confidence in Japanese products.
Automobiles, electronics, precision instruments, food, pharmaceuticals and countless other products benefited from a culture in which people took pride in producing something slightly better than what the customer explicitly requested.
This is closely related to the spirit of omotenashi.
Omotenashi is not simply customer service.
It represents the idea of anticipating needs before the customer even expresses them.
Applied to manufacturing, the philosophy becomes:
Do not merely satisfy the specification. Deliver something better than expected.
That philosophy has tremendous value.
But it also contains a trap.
When Omotenashi Becomes a Burden
Every additional quality requirement has a cost.
A tighter specification may increase batch rejection.
An unnecessary test requires analysts, equipment, reagents and documentation.
An additional manufacturing control may increase complexity.
An excessively conservative acceptance criterion can create deviations and OOS investigations without producing a meaningful improvement in patient protection.
Additional documentation requires additional review.
Additional review requires additional people.
And additional complexity makes change increasingly difficult.
Eventually, an organization can reach a strange situation:
The quality system itself becomes a source of operational risk.
This is particularly important for pharmaceutical startups and biotechnology ventures.
Large companies may be able to absorb unnecessary complexity.
Small organizations cannot.
For a startup, over-specification can consume limited capital, delay development and create manufacturing requirements that become extremely difficult to maintain during scale-up and commercialization.
GMP Does Not Mean “Make Everything Perfect”
This distinction is particularly important in GMP and GCTP environments.
The objective of pharmaceutical quality is not to create the most beautiful possible product or the largest possible quality system.
The objective is to consistently manufacture a product that is suitable for its intended use and protects patients.
Modern pharmaceutical quality management increasingly emphasizes concepts such as:
science-based decision-making, risk-based approaches, product and process understanding, and lifecycle management.
This leads to a very different question.
Instead of asking:
“Can we make the specification stricter?”
we should ask:
“What specification is scientifically justified?”
Instead of:
“Can we test more?”
ask:
“What risk does this test actually control?”
Instead of:
“Would more documentation be safer?”
ask:
“What information is necessary to demonstrate control?”
These are fundamentally different approaches to quality.
The Hidden Cost of a Narrow Specification
Imagine that the scientifically justified acceptance range for a particular quality attribute is relatively broad.
A Japanese organization voluntarily establishes a much narrower internal specification because it wants to ensure “higher quality.”
At first, this sounds excellent.
But what happens later?
Manufacturing scale increases.
Process variability becomes visible.
Technology transfer begins.
A second manufacturing site is introduced.
A CDMO becomes involved.
Suddenly, the unnecessarily narrow specification becomes difficult to maintain.
Batches that are scientifically acceptable may now fail the company’s own standard.
Investigations increase.
Manufacturing flexibility decreases.
And changing the specification itself may require significant justification and change control.
What originally looked like higher quality has become lower operational robustness.
That is the paradox of over-spec.
Are We Protecting the Patient—or the Straight Cucumber?
This is the question I believe Japanese quality professionals should occasionally ask themselves.
Suppose two products are equivalent in safety, efficacy and clinically meaningful quality.
One satisfies all scientifically justified requirements.
The other satisfies several additional internal requirements that have little or no impact on the patient.
Is the second product really “higher quality”?
Or have we simply created a pharmaceutical version of the straight cucumber?
This distinction matters.
Because resources spent controlling attributes without meaningful impact cannot be spent elsewhere.
Quality resources are finite.
Time is finite.
People are finite.
Capital is finite.
Especially in drug development.
From “Higher Quality” to “Appropriate Quality”
Japan should not abandon its quality culture.
Quite the opposite.
Precision, responsibility, craftsmanship and consideration for the end user are enormous strengths.
But perhaps the next evolution of Japanese quality culture is not about making standards continuously stricter.
It is about knowing where strictness creates value — and where it does not.
The future may therefore require a transition:
From maximum quality to appropriate quality.
From experience alone to science and risk.
From adding controls to designing controls.
From “just in case” to “because this risk matters.”
And ultimately:
From rejecting the crooked cucumber to understanding why its shape does—or does not—matter.
Over-Spec Can Be a Strength—If We Know When to Stop
There is something admirable about Japanese over-spec culture.
It says:
“Even if the customer does not notice, we will notice.”
That philosophy helped build Japan’s reputation for quality.
We should not lose it.
But global pharmaceutical development requires another capability:
knowing when enough is enough.
Global standards should not necessarily be treated as a minimum from which every Japanese organization must automatically move upward.
Sometimes the internationally accepted, scientifically justified standard is precisely where the specification should be.
Quality is not a competition to see who can create the strictest requirement.
Quality is the discipline of defining what truly matters, controlling it reliably, and being able to explain why.
The crooked cucumber may therefore have something important to teach the Japanese pharmaceutical industry.
It does not ask us to lower quality.
It asks us a much more difficult question:
What exactly do we mean by “quality”?